In This Article:
CervoMed (NASDAQ:CRVO) Full Year 2024 Results
Key Financial Results
-
Revenue: US$9.74m (up 36% from FY 2023).
-
Net loss: US$16.3m (loss widened by US$14.1m from FY 2023).
-
US$2.02 loss per share (further deteriorated from US$0.82 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
CervoMed Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 4.3%. Earnings per share (EPS) missed analyst estimates by 9.0%.
Looking ahead, revenue is expected to decline by 1.9% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 20%.
Performance of the American Biotechs industry.
The company's shares are up 308% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 5 warning signs for CervoMed (3 don't sit too well with us!) that you need to be mindful of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.